Fidelity Blue Chip Growth ETFFBCG
FBCG
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
700% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 7
265% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 23
180% more funds holding in top 10
Funds holding in top 10: 5 [Q3] → 14 (+9) [Q4]
175% more capital invested
Capital invested by funds: $1.04B [Q3] → $2.86B (+$1.82B) [Q4]
50.5% more ownership
Funds ownership: 48.43% [Q3] → 98.94% (+50.5%) [Q4]
35% more funds holding
Funds holding: 133 [Q3] → 179 (+46) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for FBCG.
Financial journalist opinion
Based on 4 articles about FBCG published over the past 30 days
Positive
24/7 Wall Street
1 week ago
3 Fidelity ETFs to Buy in March to Generate Big Passive Income In Retirement
Retail investors do not need to worry about picking individual stocks to ensure steady returns.
Positive
ETF Trends
1 week ago
Fidelity's Blue Chip Growth ETF Makes Sense in All Market Environments
Many investors favor blue chip stocks for their stability. This stability makes a blue chip ETF a familiar option during periods of market and economic stress.
Neutral
Seeking Alpha
3 weeks ago
Undercovered ETFs: Growth, Income, TIPS, Poland +
The 'Undercovered' Dozen series highlights 12 lesser-known ETFs offering potential investment opportunities for investors. Kurtis Hemmerling shares a bearish take on iShares Russell Top 200 Growth ETF due to poor factor implementation, despite its strong historical performance. Goldman Sachs Nasdaq-100 Core Premium Income ETF is given a buy from Jonathan Weber for income-oriented investors, combining a 10% dividend yield with tech exposure.
Positive
24/7 Wall Street
4 weeks ago
5 Actively Managed ETFs That Outperformed Warren Buffett Last Year
Warren Buffett has outperformed the S&P 500 for many years, and he continues to deliver impressive gains for investors.
Neutral
Seeking Alpha
1 month ago
FBCG: Strong Historical Returns But High Volatility And Fees
FBCG offers investors exposure to blue chip U.S. large cap growth equities. The fund's gross expense ratio of 0.60% is significantly higher than comparable index ETFs and somewhat higher than comparable active ETFs. FBCG has delivered solid performance historically but has done so with elevated volatility.
Positive
Seeking Alpha
1 month ago
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions.
Neutral
ETF Trends
1 month ago
VIDEO: ETF of the Week: FBCG
On this episode of “ETF of the Week” podcast, VettaFi's Head of Research Todd Rosenbluth joined Chuck Jaffe of Money Life to talk about the Fidelity Blue Chip Growth ETF (FBCG). Chuck Jaffe: One fund, on point for today; the expert to talk about it.
Neutral
ETF Trends
2 months ago
ETF of the Week: Fidelity Blue Chip Growth ETF (FBCG)
VettaFi's Head of Research Todd Rosenbluth discussed the Fidelity Blue Chip Growth ETF (FBCG) on this week's “ETF of the Week” podcast with Chuck Jaffe of “Money Life.” For more news, information, and analysis, visit VettaFi | ETF Trends.
Positive
Zacks Investment Research
2 months ago
Equity Dominates ETF Inflows at the Start of 2025
Investors poured in 31.7 billion in capital to start 2025, with U.S. equity ETFs leading the way.
Positive
Zacks Investment Research
2 months ago
Blue-Chip ETF (FBCG) Hits New 52-Week High
For investors seeking momentum, Fidelity Blue Chip Growth ETF FBCG is probably on the radar. The fund just hit a 52-week high and has moved up 46.4% from its 52-week low of $32.91 per share.
Charts implemented using Lightweight Charts™